Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of [177Lu]Lu-PSMA-I&T dosimetry in metastatic castration-resistant prostate cancer
2026-526519-12-00Phase 2Authorised
- Sponsor
- University Hospital of North Norway
- Start
- Oct 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2 trial of lutetium Lu 177 PSMA I&T, sponsored by University Hospital of North Norway. Planned start Oct 2026; status: authorised.
02
Drugs
lutetium Lu 177 PSMA I&T
Beyond the preview
Go deeper on 2026-526519-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526519-12-00.